Get the Stockscreener App
9.30
10.32%
0.87
Amylyx Pharmaceuticals Inc stock is traded at $9.30, with a volume of 2.72M.
It is up +10.32% in the last 24 hours and up +18.17% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$8.43
Open:
$8.47
24h Volume:
2.72M
Relative Volume:
1.98
Market Cap:
$829.26M
Revenue:
$380.79M
Net Income/Loss:
$49.27M
P/E Ratio:
13.29
EPS:
0.7
Net Cash Flow:
$10.68M
1W Performance:
+16.25%
1M Performance:
+18.17%
6M Performance:
+181.82%
1Y Performance:
+318.92%
1-Day Range:
$8.46
$9.378
1-Week Range:
$7.63
$9.378
52-Week Range:
$2.045
$9.378
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
9.30 | 712.45M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) - MSN
Signal strength of Amylyx Pharmaceuticals Inc. stock in tech scannersEntry Point & Free AI Powered Buy and Sell Recommendations - Newser
Amylyx Pharmaceuticals (AMLX): A High-Conviction Biotech Play with Avexitide's Groundbreaking Potential - AInvest
Analysts Reaffirm 'Buy' Ratings on Amylyx Pharmaceuticals with High Price Targets - AInvest
Amylyx Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Full technical analysis of Amylyx Pharmaceuticals Inc. stockMarket Growth Report & Entry Point Confirmation Alerts - Newser
What data driven models say about Amylyx Pharmaceuticals Inc.’s futureMarket Movers & Advanced Swing Trade Entry Plans - Newser
Can Amylyx Pharmaceuticals Inc. stock outperform in a bear marketGold Moves & Weekly High Potential Alerts - kangso.co.kr
Market reaction to Amylyx Pharmaceuticals Inc.’s recent newsWeekly Trade Recap & Breakout Confirmation Alerts - Newser
How Amylyx Pharmaceuticals Inc. stock performs during market volatilityChart Signals & Safe Entry Momentum Tips - Newser
Can trapped investors hope for a rebound in Amylyx Pharmaceuticals Inc.Market Trend Report & Growth Oriented Trading Recommendations - Newser
Understanding Amylyx Pharmaceuticals Inc.’s price movementPortfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Identifying reversal signals in Amylyx Pharmaceuticals Inc.July 2025 PostEarnings & Verified Chart Pattern Signals - Newser
Analyzing Amylyx Pharmaceuticals Inc. with multi timeframe chartsAnalyst Upgrade & Weekly High Conviction Ideas - Newser
11 Best Single Digit Stocks to Buy According to Hedge Funds - Insider Monkey
Amylyx Pharmaceuticals’ Promising Earnings Call Highlights - MSN
Can Amylyx Pharmaceuticals Inc. recover in the next quarterQuarterly Performance Summary & Verified Chart Pattern Trade Signals - Newser
Is Amylyx Pharmaceuticals Inc. reversing from oversold territoryPrice Action & Real-Time Volume Trigger Notifications - Newser
Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attention2025 Historical Comparison & Reliable Volume Spike Trade Alerts - 선데이타임즈
What technical models suggest about Amylyx Pharmaceuticals Inc.’s comeback - Newser
Drawdown in Amylyx Pharmaceuticals Inc. May Be Nearing EndMarket Risk Summary & Weekly Stock Breakout Alerts - metal.it
Will Amylyx Pharmaceuticals Inc. rebound enough to break evenMarket Sentiment Report & Real-Time Market Sentiment Alerts - Newser
Amylyx Pharmaceuticals Inc. Inches Above Key Support — Safe to Hold2025 Technical Patterns & Real-Time Market Sentiment Alerts - sundaytimes.kr
Has Amylyx Pharmaceuticals Inc. found a price floorWeekly Investment Recap & High Accuracy Trade Signal Alerts - Newser
What recovery options are there for Amylyx Pharmaceuticals Inc.Market Activity Summary & Consistent Income Trade Recommendations - Newser
Amylyx Pharmaceuticals Inc. Earnings Report Breakdown: What Investors Should Know2025 Analyst Calls & Fast Moving Market Watchlists - Newser
XTX Topco Ltd Sells 13,834 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Will Amylyx Pharmaceuticals Inc. benefit from geopolitical trendsMarket Trend Summary & Low Risk Entry Point Tips - newsyoung.net
Can Amylyx Pharmaceuticals Inc. ride the EV waveExit Point & Risk Managed Investment Entry Signals - newsyoung.net
Will Amylyx Pharmaceuticals Inc. benefit from rising consumer demandTrend Confirmation Stock Picks - thegnnews.com
Will Breakout in Amylyx Pharmaceuticals Inc. Sustain Through Next WeekAI Driven Stock Trend Forecast Shows Momentum Shift - beatles.ru
Amylyx Pharmaceuticals Advances ALS Treatment with AMX0114 Clinical Trial - MSN
Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline - MSN
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2025 Earnings Call Transcript - Insider Monkey
Amylyx Reports Q2 EPS of 46c, Meets Consensus Estimate - AInvest
Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide’s Advancements - TipRanks
Amylyx Pharmaceuticals Q2 2025 Earnings Preview - MSN
Amylyx Pharmaceuticals: Progress in Trials and Financials - TipRanks
Amylyx Pharmaceuticals: Strategic Progress in Neurodegenerative Therapies and the Path to Long-Term Value - AInvest
Amylyx in 2026: A High-Risk, High-Reward Biotech Catalyst Play - AInvest
Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - Yahoo Finance
Amylyx Pharmaceuticals' Q2 2025: Key Contradictions in PBH Patient Estimates, Trial Analysis, and Market Opportunities - AInvest
Amylyx Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amylyx Pharmaceuticals’ Phase 3 Study on Avexitide: A Potential Game-Changer for Post-Bariatric Hypoglycemia - TipRanks
Promising Future for Amylyx Pharmaceuticals: Buy Rating Backed by Avexitide’s Market Potential - TipRanks
Amylyx (AMLX) Q2 Net Loss Narrows 43% - Nasdaq
Transcript : Amylyx Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results - BioSpace
Amylyx Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Amylyx Pharma Q2 net loss wider than expected as R&D costs increase - TradingView
Amylyx Pharmaceuticals: A Biotech Undervalued by Momentum and Milestones - AInvest
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amylyx Pharmaceuticals Inc Stock (AMLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mazzariello Gina | Chief Legal Officer |
Aug 12 '25 |
Sale |
8.07 |
15,000 |
121,102 |
171,969 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):